For laboratory research use only. Not for human or veterinary use.

Same-day dispatch on orders before 4 PM ET · Support

5-Amino-1MQ: origin, structure and research history

Research Library › Mitochondrial & Coenzyme

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). It is often sold alongside peptides, but it is not a peptide. It came out of a medicinal chemistry program led by Stanley Watowich and Harshini Neelakantan at the University of Texas Medical Branch (UTMB), published in 2017 and 2018. As of 23 Oct 2026 it is not approved as a drug by the FDA.

Key facts

TypeSmall-molecule quinolinium compound (not a peptide)
Chemical name5-amino-1-methylquinolinium; usually supplied as the iodide salt (CAS 42464-96-0, C10H11N2·I, MW 286.11)
First described2017 structure-activity study (Journal of Medicinal Chemistry); 2018 follow-up (Biochemical Pharmacology)
Developed byStanley Watowich, Harshini Neelakantan and colleagues, University of Texas Medical Branch, Galveston
Designed targetNicotinamide-binding (substrate) site of NNMT
PatentsWO2018183668A1; US 11,401,243 B2 (granted 2 Aug 2022, University of Texas System)
Regulatory status (Oct 2026)Not FDA-approved; not on FDA's 503A or 503B nomination lists or the Category 2 list

Who developed it

5-Amino-1MQ comes from the laboratory of biochemist Stanley Watowich at the University of Texas Medical Branch (UTMB) in Galveston, Texas. In 2017, Harshini Neelakantan, Watowich and co-authors published a structure-activity study in the Journal of Medicinal Chemistry. They screened N-methylated quinolinium, isoquinolinium, pyridinium and benzimidazolium/benzothiazolium analogues for their ability to inhibit NNMT, and found the quinolinium scaffold the most promising, with activity in the low-micromolar range [1].

A 2018 paper in Biochemical Pharmacology extended this work to methylquinolinium compounds with primary amine substitutions. It examined how well they crossed membranes and how selective they were [2]. The related patent application lists Watowich, Neelakantan, Stanton McHardy and Hua-Yu Wang as inventors and names 5-amino-1-methylquinolinium iodide among the compounds [3]. The corresponding U.S. patent was granted in 2022 and is assigned to the University of Texas System [4]. Part of the program was funded by a U.S. Department of Defense award to Watowich (2015 to 2017) [5].

What it was designed to target

NNMT is an enzyme that transfers a methyl group from S-adenosylmethionine (SAM) to nicotinamide, a form of vitamin B3, producing 1-methylnicotinamide (1-MNA) [6]. 5-Amino-1MQ was designed as a small, positively charged mimic of the nicotinamide substrate. It is meant to occupy the enzyme’s nicotinamide-binding pocket. Docking models in the 2017 study were used to explain how quinolinium analogues sit in that site [1].

In biochemical assays, 5-Amino-1MQ is reported to inhibit NNMT with an IC50 of about 1.2 micromolar and is described as a substrate-site-selective inhibitor [7]. The 2018 cell-culture work reported lower 1-MNA levels in cultured cells, consistent with on-target NNMT inhibition. The same work found no inhibition of related SAM-dependent methyltransferases or enzymes of the NAD+ salvage pathway [2].

Why it was created

Academic studies in the 2010s linked NNMT activity to the regulation of nutrient metabolism in liver and fat tissue, which made the enzyme a subject of interest for small-molecule research [6]. The UTMB compounds were originally investigated in a research program on obesity-linked metabolic disease. The Department of Defense project behind part of the work was titled around obesity-linked osteoarthritis and metabolic disease among veterans [5]. The goal was a selective, cell-permeable research tool for NNMT [1, 2].

Research timeline

  • 2015: Department of Defense award to Stanley Watowich for NNMT inhibitor discovery (30 Sep 2015 to 29 Mar 2017) [5].
  • 30 Mar 2017: Priority date of the quinoline-derived NNMT inhibitor patent family [3].
  • 2017: Structure-activity study of quinolinium NNMT inhibitors published in the Journal of Medicinal Chemistry [1].
  • 2018: Selectivity and membrane-permeability study published in Biochemical Pharmacology (vol. 147) [2].
  • 4 Oct 2018: International application WO2018183668A1 published [3].
  • 2 Aug 2022: U.S. Patent 11,401,243 B2 granted [4].

Regulatory status as of October 2026

As of 23 Oct 2026, 5-Amino-1MQ is not approved by the FDA for any use, and no approved drug product contains it. It does not appear on FDA’s list of bulk drug substances nominated for 503A compounding (updated 14 May 2026) [8], on the 503B nomination list [9], or on FDA’s Category 2 list of substances that may present significant safety risks (current as of 22 Apr 2026) [10]. It was not among the peptides and related substances scheduled for the FDA Pharmacy Compounding Advisory Committee’s 2026 meetings [11]. It is available only as a research chemical.

Available from Kalibra Labs

Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.

Look up a Certificate of Analysis by lot number →

Frequently asked questions

Is 5-Amino-1MQ a peptide?

No. 5-Amino-1MQ (5-amino-1-methylquinolinium) is a small organic molecule built on a quinoline ring, not a chain of amino acids. It is usually supplied as an iodide salt.

Who developed 5-Amino-1MQ?

It came from Stanley Watowich’s laboratory at the University of Texas Medical Branch, with Harshini Neelakantan as lead author of the 2017 and 2018 papers describing the compound series.

What does 5-Amino-1MQ target?

It was designed to bind the nicotinamide site of nicotinamide N-methyltransferase (NNMT), an enzyme that methylates nicotinamide using S-adenosylmethionine.

Is 5-Amino-1MQ FDA approved?

No. As of 23 Oct 2026 it is not FDA-approved and is not on FDA’s 503A or 503B compounding nomination lists. It is sold only for laboratory research.

Sources

  1. Neelakantan H, Wang HY, Vance V, Hommel JD, McHardy SF, Watowich SJ. Structure-Activity Relationship for Small Molecule Inhibitors of Nicotinamide N-Methyltransferase. J Med Chem. 2017;60(12):5015-5028. doi:10.1021/acs.jmedchem.7b00389 Link
  2. Neelakantan H, Vance V, Wetzel MD, Wang HYL, McHardy SF, Finnerty CC, Hommel JD, Watowich SJ. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018;147:141-152. doi:10.1016/j.bcp.2017.11.007 Link
  3. Watowich S, Neelakantan H, McHardy S, Wang HY. Quinoline derived small molecule inhibitors of nicotinamide N-methyltransferase (NNMT) and uses thereof. WO2018183668A1 (priority 30 Mar 2017; published 4 Oct 2018). Link
  4. US 11,401,243 B2. Quinoline derived small molecule inhibitors of nicotinamide N-methyltransferase (NNMT) and uses thereof. Granted 2 Aug 2022; assignee University of Texas System. Link
  5. UTMB Research Experts. Discovery of Novel N-Nicotinamide Methyltransferase Inhibitors to Combat Obesity-Linked Osteoarthritis and Metabolic Disease Among Veterans and Beneficiaries (PI: S. Watowich; Award W81XWH1510372). Link
  6. Hong S, Moreno-Navarrete JM, Wei X, et al. Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization. Nat Med. 2015;21(8):887-894. doi:10.1038/nm.3882 Link
  7. Sigma-Aldrich. 5-Amino-1-methylquinolinium iodide, product SML2832 (CAS 42464-96-0), product information. Link
  8. U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (updated 14 May 2026). Link
  9. U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the FD&C Act (updated 21 Mar 2025). Link
  10. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 22 Apr 2026). Link
  11. Latham & Watkins. FDA on Peptides: A New Landscape for Compounders (2026), summarizing 91 Fed. Reg. 20465 (16 Apr 2026) and the PCAC meeting agendas. Link

Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.

For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.

0
Your Cart
Empty CartYour cart is emptyReturn to Shop
Scroll to Top